Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment
暂无分享,去创建一个
John Seibyl | Ana M. Catafau | Osama Sabri | Santiago Bullich | Norman Koglin | Henryk Barthel | Susan De Santi | Aleksandar Jovalekic | J. Seibyl | S. de Santi | O. Sabri | H. Barthel | A. Catafau | N. Koglin | S. Bullich | Aleksandar Jovalekic
[1] Osama Sabri,et al. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios? , 2016, The Journal of Nuclear Medicine.
[2] C. Rowe,et al. OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET , 2016, Alzheimer's & Dementia.
[3] John Seibyl,et al. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study , 2016, The Journal of Nuclear Medicine.
[4] John Seibyl,et al. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans , 2016, The Journal of Nuclear Medicine.
[5] J. Schnabel,et al. Classification of amyloid status using machine learning with histograms of oriented 3D gradients , 2016, NeuroImage: Clinical.
[6] Osama Sabri,et al. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[7] T. Montine,et al. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques. , 2015, JAMA neurology.
[8] Lennart Thurfjell,et al. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data , 2015, Alzheimer's & Dementia.
[9] John Seibyl,et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.
[10] C. Rowe,et al. Amyloid imaging in therapeutic trials: The quest for the optimal reference region , 2015, Alzheimer's & Dementia.
[11] Sterling C. Johnson,et al. High amyloid load is associated with episodic memory decline and incident mild cognitive impairment in middle-aged adults in the wisconsin registry for Alzheimer’s prevention (WRAP) , 2015, Alzheimer's & Dementia.
[12] C. Rowe,et al. 18F-Florbetaben (FBB) PET SUVR quantification: Which reference region? , 2015 .
[13] M. Sabbagh,et al. Age dependence of brain β-amyloid deposition in Down syndrome , 2015, Neurology.
[14] Lennart Thurfjell,et al. Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.
[15] J. Pariente,et al. Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[16] C. Rowe,et al. 18F-florbetaben Aβ imaging in mild cognitive impairment , 2013, Alzheimer's Research & Therapy.
[17] R. Coleman,et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.
[18] W. Kukull,et al. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.
[19] Christian Gaser,et al. Models of the Aging Brain Structure and Individual Decline , 2012, Front. Neuroinform..
[20] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[21] C. Rowe,et al. Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.
[22] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[23] E. S. Pearson,et al. THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .
[24] C. Rowe,et al. 18 F-florbetaben Ab imaging in mild cognitive impairment , 2013 .
[25] Nick C Fox,et al. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. , 2011, Brain : a journal of neurology.
[26] S. Holm. A Simple Sequentially Rejective Multiple Test Procedure , 1979 .